Business Context and Reporting Period
Company: Acacia Research Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and Six Months Ended June 30, 1996
Business Overview: The Company provides capital management services and makes direct investments in emerging corporations. Key portfolio companies include Whitewing Labs, MerkWerks, CombiMatrix, and Soundview Technologies. The Company also acts as a general partner for private investment partnerships and an advisor to offshore funds.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1996 |
Six Months Ended June 30, 1995 |
|---|---|---|
| Total Revenues | $3,213,334 | $841,810 |
| Net Income | $1,579,352 | $335,958 |
| Earnings Per Share (Diluted) | $0.59 | $0.14 |
| Cash and Cash Equivalents | $935,243 | $394,724 |
| Working Capital | $2,194,174 | N/A |
| Current Ratio | 5.4 to 1 | N/A |
| Net Cash from Operations | $325,723 | ($504,728) |
| Total Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Surge: Total revenues increased by 282% ($2.37 million) compared to the prior year period. This was driven primarily by a one-time unrealized gain of $1.07 million from the Whitewing Labs IPO and a $1.4 million management fee received in stock from Soundview Technologies.
- Profitability: Net income increased by 370% to $1.58 million. The effective tax rate increased significantly due to the recognition of deferred tax liabilities on the Whitewing Labs gain and current taxes on the Soundview management fee.
- Cash Flow Reversal: Operating cash flow turned positive ($325,723) from a negative position ($504,728) in the prior year, despite significant investing outflows of $375,591 for new equity investments.
- Asset Growth: Total assets grew from $4.46 million to $6.94 million, largely due to new investments in unconsolidated subsidiaries and partnerships.
Guidance, Outlook, and Risks
- Outlook: Management anticipates that cash generated from operations and working capital reserves will be adequate to fund recurring capital expenditures for fiscal 1996 and the foreseeable future. Future gains similar to the Whitewing Labs unrealized gain are anticipated as other subsidiaries pursue public offerings.
- Revenue Volatility: Gains from sales of securities are subject to substantial fluctuation. The Company is currently prohibited from selling Whitewing Labs shares until February 1997.
- Concentration Risk: Notes receivable totaling $1.32 million are due from two individuals, creating a concentration of credit risk, though these are collateralized by stock and personally guaranteed.
- Bank Balances: The Company maintains cash balances of $646,287 in excess of insured amounts at Southern California financial institutions.
Investor Verification Checklist
- Non-Cash Revenue: Verify the sustainability of revenue streams, noting that $2.47 million of the $3.21 million revenue was derived from non-cash items (unrealized gains and stock-based management fees).
- Whitewing Labs Valuation: Confirm the market value of the Company's 19.4% stake in Whitewing Labs, which is carried at book value but has a reported market value of approximately $2.2 million.
- Notes Receivable Collateral: Assess the liquidity and value of the collateral securing the $1.4 million in notes receivable from individuals.
- Deferred Tax Assets: Review the realizability of the $930,182 in gross deferred tax assets, which are significant relative to the Company's size.
- Stock Option Dilution: Monitor the impact of the 1996 Stock Option Plan and Executive Bonus Plan, which reserved 610,000 shares for future grants.